Presentations
M2SR Cell-Based Flu Vaccine and Platform for Infectious Diseases – WVC 2023 Presentation
PDF · Published 2026-11-14 · 2 min read
Presentation
Dr. Pamuk Bilsel, Chief Scientific Officer of FluGen, presented this talk at the World Vaccine Congress in Barcelona on 19 October 2023. It covers the M2SR influenza vaccine platform end to end: virus design, cell-based manufacturing, formulation stability, and clinical immunogenicity and efficacy results.
Two sections of the presentation report formulation work in which InVitria materials were used. M2SR vaccine virus was produced in M2Vero cells using chemically defined OptiVERO® medium, and Exbumin® recombinant human serum albumin (rHSA) was evaluated as a stabilizer for the drug substance.
Why This Matters
Live viral vaccines lose potency during storage and handling. Human serum albumin is a long-established stabilizer for this purpose, but plasma-derived albumin introduces donor-pool variability and supply risk into a formulation that has to hold titer for a year or more. The data in this presentation show a recombinant albumin performing that stabilizing role across three influenza strains.
- At 2–8 °C, sucrose phosphate buffer with Exbumin rHSA held titer substantially longer than sucrose phosphate buffer alone for H3N2, H1N1, and Yamagata B M2SR viruses.
- Through 16 freeze/thaw cycles, histidine buffer with Exbumin rHSA preserved titer better than histidine buffer alone or with CMC.
- Virus was produced in an animal-origin-free process using chemically defined OptiVero medium.
Presentation Contents
- M2SR design: an M2-deleted single-replication influenza virus that infects cells and expresses viral proteins without producing infectious progeny
- Virus rescue in production Vero cells across influenza A and B strains, including GMP banks
- Cell-based manufacturing scale-up on microcarriers from 2 L through 50 L GMP scale
- Drug substance stability at 2–8 °C and through repeated freeze/thaw, with and without rHSA
- Clinical results in roughly 700 subjects aged 2–85, including mucosal, humoral, and cellular immune responses and a drifted-strain challenge study
- The M2SR platform applied as a dual COVID/influenza vaccine candidate
About This Resource
This presentation is the work of FluGen, Inc. and its collaborators. InVitria supplied the OptiVero® chemically defined medium and Exbumin® rHSA referenced in the manufacturing and stability sections, and is sharing the presentation here with that context.
Download
Download PDFProducts Mentioned
-
Exbumin®
Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.
-
OptiVERO®
Chemically defined, blood-free complete medium for VERO cell expansion and virus production in 2D flask and 3D microcarrier formats.
More resources
Keep reading.
Recombinant Animal-Free Albumin Enhances Infectious Lentiviral Vector Yields – ASGCT 2026 Presentation
From Licensed Precedent to Next-Generation Ebola Vaccines – WVC Europe 2026 Presentation
Talk to a Scientist
See how rHSA performs in your media.
Send us your cell line and formulation and we will help you design a side-by-side evaluation against your current albumin.